Lalu Galih Pratama Rinjani

Lalu Galih Pratama Rinjani

Auto-generated profile, based on publicly available information

Lalu Galih Pratama Rinjani

Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Hospital, Surabaya, Indonesia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2023 in Biomolecular and Health Science Journal
Verified
Journal Article
Open access
AAAndrianto Andrianto
Andrianto Andrianto
LRLalu Galih Pratama Rinjani
Lalu Galih Pratama Rinjani
RNRicardo Adrian Nugraha
Ricardo Adrian Nugraha
PHPrimasitha Maharany Harsoyo
Primasitha Maharany Harsoyo
MJMichael Jonatan
Michael Jonatan
TMTakashi Matsumoto
Takashi Matsumoto
Introduction: Around 50% of patients with heart failure (HF) have an existing iron deficiency (ID), with or without anemia. With such a high prevalence, more research is underway to determine whether addressing ID can improve HF. Aims: This study aimed to critically evaluate the beneficial effects of intravenous iron administration for chronic HF. Methods: Studies were searched in Medline, Embase, and Cochrane for trials investigating the effect of iron supplementation on chronic HF patients. Outcomes of HF and all-cause hospitalizations, as well as cardiovascular-related and all-cause mortalities, were observed. We calculated the odds ratios (ORs) using fixed and random-effect models. The bias was evaluated by funnel plots and Egger's regression tests. Statistical analysis was conducted using RevMan (version 5.4.1). Results: Five studies with a total sample size of 1646 subjects were included in this meta-analysis and systematic review. Four studies reported the all-cause mortality of intravenous iron supplementation for HF. None of them provided evidence for the association between intravenous iron supplementation and all-cause mortality (OR = 0.75, 95% confidence interval [CI] 0.38–1.50, P = 0.42, I 2 = 0%, fixed effect). Four studies established that intravenous iron therapy significantly decreased hospitalization due to HF (OR = 0.56, 95% CI: 0.34–0.94, P = 0.03, I 2 = 53%, random effect). Conclusion: Iron supplementation does confer the benefit of iron supplementation in patients with chronic, stable HF with regard to HF hospitalization despite not showing significant associations in all-cause hospitalization, cardiovascular death, or all-cause mortality.